SGLT-2 inhibitors, a relatively new classification of medications used primarily in the treatment of type 2 diabetes, also have implications for use in individuals with chronic kidney disease. Learn more about SGLT-2 inhibitors, dosing for patients with renal disease, possible side effects, cost, and potential funding sources for renal patients who may benefit from treatment with these medications.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 11/8/2022.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
There are no other disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: American Nephrology Nurses Association (ANNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP17499.
ANNA urges participants to be aware of the CNE requirements for relicensure in the states in which they hold a license.
Learning Outcome: Upon completion of this activity the learner will describe how a drug used to manage type 2 diabetes may have implications and possible side effects for individuals with chronic kidney disease.